Pain News and Research

Latest Pain News and Research

Preliminary research findings from Kessler Foundation’s Ekso device study on SCI

Kessler Foundation has released preliminary research findings from its clinical study of the wearable robotic exoskeletal device, Ekso. Gail Forrest, PhD, assistant director of Human Performance and Engineering Research, presented the Ekso research data on September 3, at the meeting of the Academy of Spinal Cord Injury Professionals at the Rio Suites in Las Vegas. Dr. Forrest directs mobility research at the Foundation, including activity-based locomotor therapy, functional electrical stimulation, and treadmill training with the LokomatPro v6, as well as Ekso.

6 Sep 2012

Expenditures for treatment of back and neck problems have nearly doubled since late 1990s

Expenditures for treatment of back and neck problems have nearly doubled since the late 1990s—mainly from increased spending for care provided by medical specialists, according to a report in the September 1 issue of Spine.

6 Sep 2012

Clinical trial to test combination of two drugs in treating fibromyalgia

A chronic pain condition and numerous gastrointestinal disorders may all be caused by a virus. That's a Tuscaloosa-based surgeon's theory likely headed for a clinical trial early next year and one drawing support from a University of Alabama researcher who studies how viruses replicate.

6 Sep 2012

Sorafenib could be effective against multiple myeloma

Research from Karolinska Institutet in Sweden shows that sorafenib, a drug used for advanced cancer of the kidneys and liver, could also be effective against multiple myeloma. The disease is one of the more common forms of blood cancer and is generally incurable.

6 Sep 2012

AMAG receives Swiss marketing authorization for ferumoxytol to treat iron deficiency anemia

AMAG Pharmaceuticals, Inc. today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorization in Switzerland for ferumoxytol, an intravenous (IV) iron therapy to treat iron deficiency anemia (IDA) in adult patients with chronic kidney disease.

6 Sep 2012

Pfizer receives FDA approval for BOSULIF to treat Ph+ chronic myelogenous leukemia

Pfizer Inc. announced today the U.S. Food and Drug Administration (FDA) has approved BOSULIF (bosutinib), an Abl and Src kinase inhibitor, for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy.

6 Sep 2012

DuraSite 2 ophthalmic drug delivery system from InSite Vision

InSite Vision Incorporated today introduced DuraSite 2, its next-generation enhanced drug delivery system which provides a broad platform for developing superior ophthalmic therapeutics.

6 Sep 2012

Corticosteroids needed after DALK to avert stromal rejection

Like those undergoing penetrating keratoplasty, patients treated with deep anterior lamellar keratoplasty may benefit from taking postoperative corticosteroids to prevent stromal rejection, report US researchers.

5 Sep 2012

Predictors for pain after breast cancer surgery unveiled

Researchers have identified that chronic preoperative pain, axillary surgery, and psychologic robustness significantly predict acute pain outcomes after breast cancer surgery.

5 Sep 2012

More focus required on hospice care for heart failure patients

End-stage heart failure patients enter hospice care closer to the time of their death, are more often referred from acute care facilities, and are more likely to die in acute care settings compared with cancer patients, show study results.

5 Sep 2012

Real-time prescription system reduces inappropriate prescribing of medications

A centralized prescription network providing real-time information to pharmacists in British Columbia, Canada, resulted in dramatic reductions in inappropriate prescriptions for opioid analgesics and benzodiazepines, widely used and potentially addictive drugs. The findings are reported in a study in CMAJ (Canadian Medical Association Journal).

5 Sep 2012

Enrollment complete in ACADIA's pimavanserin Phase III trial for Parkinson's disease psychosis

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced the completion of enrollment in its ongoing pivotal Phase III trial with pimavanserin in patients with Parkinson's disease psychosis (PDP).

5 Sep 2012

Texas hospitals under scrutiny: Parkland's record penalty, how Houston treats heart attacks

Texas officials fined Dallas' Parkland Memorial Hospital a record $1 million for patient safety violations in the wake of intense federal oversight that could cost hundreds of millions of dollars if errors aren't corrected.

5 Sep 2012

NIH funded researchers identify and explore different aspects of anesthesia

Anesthesia helps many of us during our lives, whether we need a local painkiller at the dentist, numbing eye drops for laser vision correction or general anesthesia for major surgery. But even though anesthetics have been used in many procedures for more than 150 years, doctors and scientists still don't know exactly how these medicines work in the body.

5 Sep 2012

Roundup: Texas probes Xerox in Medicaid overbilling; Miss. abortion clinic fights to stay open

Texas authorities are investigating whether Xerox Corp. played a role in allowing dentists to allegedly overbill the state's Medicaid system by millions of dollars.

5 Sep 2012

Zalicus commences first of two Z160 Phase 2a clinical studies for chronic neuropathic pain

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that it has initiated the first of two Phase 2a clinical studies with Z160, its first-in-class, oral, state-dependent, selective N-type calcium channel blocker for the treatment of chronic neuropathic pain indications.

5 Sep 2012

FDA approves Bosulif to treat chronic myelogenous leukemia

The U.S. Food and Drug Administration today approved Bosulif (bosutinib) to treat chronic myelogenous leukemia (CML), a blood and bone marrow disease that usually affects older adults.

5 Sep 2012

Young doctors seek to alter practice of medicine; Medical schools push training in addiction

The Associated Press examines how tech-savy young doctors are changing medicine, and KHN looks at efforts to train doctors to recognize how addictions complicate other health problems.

5 Sep 2012

Biokine, BioLineRx sign license agreement to develop and commercialize BL-8040 for AML

BioLineRx Ltd., a biopharmaceutical drug development company, announced today that it has signed an exclusive, worldwide license agreement with Biokine Therapeutics Ltd., a Clal Biotechnology Industries portfolio company, for the development and commercialization of BL-8040 (formerly BKT-140), a Phase II ready drug candidate for the treatment of acute myeloid leukemia (AML), as well as other types of hematological cancer.

4 Sep 2012

First Edition: September 4, 2012

Today's early morning highlights from the major news organizations, including previews of the Democratic convention and a New York Times analysis of how the Obama and Romney campaigns vary on Medicaid policy.

4 Sep 2012

Pain News and Research

Latest Pain News and Research

Preliminary research findings from Kessler Foundation’s Ekso device study on SCI

Expenditures for treatment of back and neck problems have nearly doubled since late 1990s

Clinical trial to test combination of two drugs in treating fibromyalgia

Sorafenib could be effective against multiple myeloma

AMAG receives Swiss marketing authorization for ferumoxytol to treat iron deficiency anemia

Pfizer receives FDA approval for BOSULIF to treat Ph+ chronic myelogenous leukemia

DuraSite 2 ophthalmic drug delivery system from InSite Vision

Corticosteroids needed after DALK to avert stromal rejection

Predictors for pain after breast cancer surgery unveiled

More focus required on hospice care for heart failure patients

Real-time prescription system reduces inappropriate prescribing of medications

Enrollment complete in ACADIA's pimavanserin Phase III trial for Parkinson's disease psychosis

Texas hospitals under scrutiny: Parkland's record penalty, how Houston treats heart attacks

NIH funded researchers identify and explore different aspects of anesthesia

Roundup: Texas probes Xerox in Medicaid overbilling; Miss. abortion clinic fights to stay open

Zalicus commences first of two Z160 Phase 2a clinical studies for chronic neuropathic pain

FDA approves Bosulif to treat chronic myelogenous leukemia

Young doctors seek to alter practice of medicine; Medical schools push training in addiction

Biokine, BioLineRx sign license agreement to develop and commercialize BL-8040 for AML

First Edition: September 4, 2012

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Pain News and Research

Latest Pain News and Research

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Newsletters you may be interested in